EMPLOYMENT AGREEMENTEmployment Agreement • November 13th, 2020 • Regencell Bioscience Holdings LTD • Medicinal chemicals & botanical products • Hong Kong
Contract Type FiledNovember 13th, 2020 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of November 12, 2020, by and between Regencell Bioscience Holdings Limited, incorporated under the laws of the Cayman Islands (the “Company”), and Yat-Gai Au, a holder of Hong Kong Identity Card Number: [ ] (the “Executive”). Except with respect to the direct employment of the Executive by the Company, the term “Company” as used herein with respect to all obligations of the Executive hereunder shall be deemed to include the Company and all of its subsidiaries and affiliated entities (collectively, the “Group”).
LOAN AGREEMENT entered into between: Mr. Yat-Gai Au (“the Lender”) And Regencell Bioscience Limited (“the Borrower”)Loan Agreement • November 13th, 2020 • Regencell Bioscience Holdings LTD • Medicinal chemicals & botanical products • Hong Kong
Contract Type FiledNovember 13th, 2020 Company Industry JurisdictionThis LOAN AGREEMENT (hereinafter referred to as the “Agreement”) is made and entered into on November 10, 2020, by and between Yat-Gai Au, a holder of Hong Kong Identity Card Number: [ ], 11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong (hereinafter referred to as the “Lender”) and Regencell Bioscience Limited, a limited company duly established under the laws of Hong Kong, having its registered office at 11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong (hereinafter referred to as the “Borrower”). The Lender and the Borrower collectively shall be referred to as the “Parties” and respectively as the “Party.”
SUPPLEMENTAL AGREEMENTSupplemental Agreement • November 13th, 2020 • Regencell Bioscience Holdings LTD • Medicinal chemicals & botanical products • Hong Kong
Contract Type FiledNovember 13th, 2020 Company Industry JurisdictionThis Supplemental Agreement (the “Supplemental Agreement”) of the Deed of Rights Transfer, Strategic Partnership and Undertaking Agreement is made and entered into on November 10, 2020 (“Effective Date”) by and between:
Dated the 1st day of January 2018 AU, SIK KEE (區錫機) AND REGENCELL BIOSCIENCE LIMITED DEED OF RIGHTS TRANSFER, STRATEGIC PARTNERSHIP AND UNDERTAKINGRegencell Bioscience Holdings LTD • November 13th, 2020 • Medicinal chemicals & botanical products • Hong Kong
Company FiledNovember 13th, 2020 Industry JurisdictionAU, SIK KEE (區錫機), the holder of Hong Kong Identity Card No. [ ] of 22/F, First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong, being the Listed Chinese Medicine Practitioner with the Listed No. of [ ] maintained by the Chinese Medicine Practitioners Board of the Chinese Medicine Council of Hong Kong (“The Chinese Medicine Practitioner”);